Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.38), $0.18 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $4.61 million versus the consensus estimate of $2.1 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.